Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.41 |
| ▸ | GALR1 | P47211 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP4 | P49662 | 1/20 | 0.37 |
| ▸ | CASP5 | P51878 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809475 | 0.92 | DNMT3A (0.47) | GALR2GALR1SIGMAR1MEN1KMT2A | |
| SCHEMBL2814408 | 0.92 | HRH4 (0.43) | EHMT2SIGMAR1DNMT3A | |
| SCHEMBL538223 | 0.91 | MAPT (0.41) | SIGMAR1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2814820 | 0.89 | DNMT3A (0.46) | SMN1; SMN2DNMT3ACASP1CASP4CASP5 | |
| SCHEMBL2808265 | 0.89 | TSHR (0.43) | MEN1KMT2ASMN1; SMN2NPSR1PKM | |
| SCHEMBL2808410 | 0.88 | HTR2A (0.45) | SIGMAR1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2809936 | 0.87 | ALDH1A1 (0.41) | SIGMAR1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2811683 | 0.87 | PTGIR (0.40) | EHMT2GALR2GALR1SMN1; SMN2NPSR1 | |
| SCHEMBL2813884 | 0.86 | HRH3 (0.44) | SIGMAR1HRH2MEN1KMT2ANPSR1 | |
| SCHEMBL2809526 | 0.86 | TSHR (0.40) | EHMT2SIGMAR1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | EHMT2 3441/4885GALR2 4756/4885GALR1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.